Characterization of human papillomavirus antibodies in individuals with head and neck cancer.

Lang Kuhs KA, Pawlita M, Gibson SP, Schmitt NC, Trivedi S, Argiris A, Kreimer AR, Ferris RL, Waterboer T
Cancer Epidemiol. 2016 42: 46-52

PMID: 27010729 · PMCID: PMC4910878 · DOI:10.1016/j.canep.2016.03.003

BACKGROUND - Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized.

METHODS - Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n=25).

RESULTS - 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n=6] and 100% [95% CI: 60-100%, n=4] compared to 0% (n=2) and 0% (n=13) for non-OPC cases.

CONCLUSIONS - HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.

Copyright © 2016 Elsevier Ltd. All rights reserved.

MeSH Terms (7)

Head and Neck Neoplasms Human papillomavirus 16 Humans Oncogene Proteins, Viral Papillomavirus Infections Repressor Proteins Seroepidemiologic Studies

Connections (1)

This publication is referenced by other Labnodes entities: